Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935673 | 0.93 | MEN1 (0.32) | ALDH1A1EPHX2EPHX1LMNA | |
| SCHEMBL2873876 | 0.88 | ESR1 (0.32) | ALDH1A1 | |
| SCHEMBL2003186 | 0.88 | ESR1 (0.32) | ALDH1A1 | |
| SCHEMBL23199284 | 0.79 | SMN1; SMN2 (0.33) | LMNA | |
| SCHEMBL23525274 | 0.79 | SMN1; SMN2 (0.33) | LMNA | |
| SCHEMBL12258481 | 0.78 | KEAP1 (0.40) | ALDH1A1LMNA | |
| SCHEMBL1008489 | 0.78 | ALDH1A1 (0.35) | ALDH1A1ACHELMNANPC1 | |
| SCHEMBL20214001 | 0.78 | CHRNB2 (0.35) | — | |
| SCHEMBL23199286 | 0.77 | MEN1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL21072118 | 0.77 | MEN1 (0.35) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| US-20220388985-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2022-12-08 | — | — | US | disclosed |
| EP-3986887-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Ribon Therapeutics Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2020257416-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3728207-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-9527830-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2755656-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| EP-2755656-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039802-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2342200-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010036630-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| CN-101304986-A | Regioselective process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | CN | disclosed |
| EP-1948597-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007050522-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388985-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | ALDH1A1 3504/4885CPN1 909/4885CPB2 1858/4885 |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | ALDH1A1 2388/4885CPN1 2582/4885CPB2 3159/4885 |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | ALDH1A1 2388/4885CPN1 2582/4885CPB2 3159/4885 |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | ALDH1A1 2388/4885CPN1 2582/4885CPB2 3159/4885 |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | ALDH1A1 2388/4885CPN1 2582/4885CPB2 3159/4885 |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | ALDH1A1 1376/4885CPN1 4690/4885CPB2 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.